Results

1–10 of 44 results for Gene Therapy

Subretinal Gene Therapy Drug AGTC-501 for X-Linked Retinitis Pigmentosa: Phase 2 Randomized Controlled Masked Multicenter Clinical Trial (Skyline) Interim Safety Results
On Demand Cases, Courses, and Papers
2022
Safety and Efficacy of Intravitreal Optogenetic Gene Therapy for Advanced Retinitis Pigmentosa
Sai H Chavala, MD
On Demand Cases, Courses, and Papers
2021
Suprachoroidal Delivery of RGX-314 for Neovascular AMD: Initial Results From the Phase II AAVIATE Study
Mark R. Barakat, MD
Annual Meeting Talks
2021
Intravitreal Gene Therapy for Neovascular AMD with ADVM-022: Results of the Phase 1 OPTIC Trial
Dante Joseph Pieramici, MD
Annual Meeting Talks
2021
Intravitreal Gene Therapy for Diabetic Macular Edema With ADVM-022: First-Time Data Presentation of Prospective, Randomized Phase 2 INFINITY Trial
Charles C Wykoff, MD, PhD, FASRS
Annual Meeting Talks
2021
Suprachoroidal Delivery of RGX-314 for Diabetic Retinopathy Without CI-DME: Early Results From the Phase II ALTITUDE Study
Dennis M. Marcus, MD
Annual Meeting Talks
2021
Preliminary Results from a First-in-human Phase I/II Gene Therapy Study (FOCUS) of Subretinally Delivered GT005, an Investigational AAV2 Vector, in Patients with Geographic Atrophy Secondary to Age-related Macular Degeneration
Jared S. Nielsen, MD, MBA
Updates from the Field
2022
Microscope-Integrated Optical Coherence Tomography Can Measure the Volume of Subretinal Blebs Created by a Suprachoroidal Approach
Ananth Sastry, MD
Annual Meeting Talks
2020
AAV-RPGR Gene Therapy for RPGR-Associated X-Linked Retinitis Pigmentosa: 6-month Results From a Phase 1/2 Clinical Trial
Michel Michaelides, BSc, MB BS, MD(Res), FRCOphth, FACS
Annual Meeting Talks
2020
Creating Blebs for Subretinal Gene Delivery
Andreas K. Lauer, MD
Annual Meeting Talks
2020